Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05629065 · ClinicalTrials.gov registry record · NA
Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)
A NA study of Breast Cancer and Gynecologic Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 800
- Enrollment target
- 1
- Study location
NCT05629065: Active NA study of Breast Cancer and Gynecologic Cancer, sponsored by Dana-Farber Cancer Institute.
NCT05629065 is a NA study of Breast Cancer and Gynecologic Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 800 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05629065, a NA study of Breast Cancer and Gynecologic Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to increase serious illness conversations (SICs) about patients goals and preferences regarding their healthcare between patients with cancer and their oncology clinicians and improved care provided near the end of life.
Primary Outcome
The numerator includes patients with any SIC documentation extracted from the Advanced Care Planning module between the date of the poor prognosis node and 60 days. The denominator is all patients randomized to the applicable study arm.
Conditions Studied
Interventions
- OTHER Clinician Nudge Email
- OTHER Patient Nudge Letter and Share questionaire
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2022-11-28 |
| Est. Completion | 2028-06 |
| Phase | NA |
What the registry record for NCT05629065 still lists
NCT05629065 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (71% lower).
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Clinician Nudge Email is the first listed.
NCT05629065 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05629065 about?
NCT05629065 is a clinical study titled "Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)". The purpose of this study is to increase serious illness conversations (SICs) about patients goals and preferences regarding their healthcare between patients with cancer and their oncology clinicians and improved care provided near the end of life.
What is the current status of trial NCT05629065?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2022-11-28. Estimated completion is 2028-06.
What conditions does trial NCT05629065 study?
This clinical trial studies the following conditions: Breast Cancer, Gynecologic Cancer, Gastrointestinal Cancer, Thoracic Cancer, Genitourinary Cancer.
What interventions are being tested in trial NCT05629065?
The interventions under investigation include: Clinician Nudge Email (OTHER), Patient Nudge Letter and Share questionaire (OTHER).
Who is sponsoring clinical trial NCT05629065?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05629065 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05629065's enrollment target sits among peer trials
800 144th of 1224 higher than 1,079 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI